TNF-α or JAK inhibitors may provide therapeutic benefit in refractory cases.<h4>Conclusion</h4>This case highlights a rare instance of delayed-onset TEN following sintilimab-based neoadjuvant therapy in gastric cancer, occurring shortly after surgical resection despite a complete pathological response. The gene discussed is TNF; the disease is toxic epidermal necrolysis.